Ketamine is a Schedule III controlled substance under the federal Controlled Substances Act. It has been classified this way since 1999, when the DEA added ketamine, including its salts and isomers, to Schedule III as a non-narcotic substance. This places it in the middle tier of drug scheduling, below the stricter Schedule I and II categories but still subject to significant legal controls.
What Schedule III Means
The Controlled Substances Act uses five schedules to classify drugs based on their medical usefulness and potential for abuse. Schedule I is the most restrictive (drugs with no accepted medical use and high abuse potential), while Schedule V is the least restrictive. Schedule III sits in the middle and applies to substances that have accepted medical uses but also carry a potential for abuse that could lead to moderate or low physical dependence, or high psychological dependence.
Ketamine fits this category because it is an effective anesthetic with legitimate clinical applications, but it can also be misused recreationally for its dissociative and hallucinatory effects. The Schedule III classification means ketamine requires a prescription from a licensed provider, and pharmacies must follow controlled substance protocols when dispensing it. Possessing ketamine without a valid prescription is a federal crime, and state laws may impose additional penalties.
Why Schedule III and Not Higher
Ketamine’s abuse potential is real but notably lower than drugs in Schedule II (like oxycodone or methamphetamine) or Schedule I (like heroin). Research published in Nature helps explain why. In animal studies, mice voluntarily took similar amounts of ketamine and cocaine, suggesting ketamine is both rewarding and reinforcing. However, the two drugs behave very differently in the brain’s reward system.
Both ketamine and cocaine boost dopamine release in the brain’s reward circuitry, but cocaine produces a prolonged dopamine surge while ketamine’s effect is much shorter. The brain has a built-in feedback system that limits dopamine release, and ketamine triggers that brake effectively. Cocaine does not. In practical terms, this means ketamine is less likely to drive the compulsive, escalating use that defines addiction. When researchers made it harder to obtain the drug, mice would work to get cocaine but gave up on ketamine. They also wouldn’t take ketamine if there was a negative consequence attached. Neither short-term nor long-term ketamine exposure produced the neural changes associated with drug craving.
The overall picture: ketamine can be pleasurable and reinforcing, but it has a low liability for addiction compared to substances in higher schedules. That distinction is central to its Schedule III placement.
Approved Medical Uses
Ketamine’s FDA-approved use is for induction and maintenance of general anesthesia. It was first approved in the United States in 1970 and has been a staple in operating rooms and emergency departments ever since, valued for its ability to provide sedation and pain relief without suppressing breathing as much as other anesthetics.
Beyond anesthesia, there has been growing interest in using ketamine at much lower doses for conditions like treatment-resistant depression and chronic pain. These uses are not FDA-approved for ketamine itself, meaning providers who offer ketamine infusions for depression are prescribing it “off-label.” Off-label prescribing is legal and common in medicine, but it means the treatment hasn’t gone through the FDA’s full approval process for that specific condition.
Esketamine: A Related but Distinct Drug
Esketamine, sold as a nasal spray under the brand name Spravato, is a close chemical relative of ketamine. It contains only one of the two mirror-image molecules found in standard ketamine (the S-enantiomer). Esketamine is also classified as Schedule III, but it has its own FDA approval specifically for treatment-resistant depression and depressive symptoms with suicidal ideation.
The rules around esketamine are considerably stricter than for generic ketamine. It can only be administered in certified healthcare settings through a restricted program called REMS (Risk Evaluation and Mitigation Strategy). Patients must take the nasal spray under direct observation of a healthcare provider and then be monitored for at least two hours afterward. Blood pressure checks are required before and after each dose. Patients are instructed not to drive or operate machinery until the next day after a full night of sleep. The drug is never dispensed for home use.
These extra safeguards exist because esketamine causes sedation and dissociation, and its abuse potential in studies was similar to that of intravenous ketamine.
How Ketamine Clinics Operate Under Schedule III
The growth of ketamine clinics offering infusions for depression and pain has raised questions about oversight. Because ketamine is Schedule III, any licensed physician can legally prescribe it off-label. There is no single federal certification process for ketamine clinics the way there is for esketamine. Instead, clinics must comply with federal controlled substance laws, state medical board regulations, and local pharmacy and facility rules.
Providers are required to follow proper drug storage, waste, and disposal measures to prevent diversion and misuse. State nursing and medical boards may issue specific guidance on who can administer ketamine infusions and what monitoring is required. The level of regulation varies significantly from state to state, which is why the quality and safety protocols at ketamine clinics can differ widely.
Legal Consequences of Misuse
Because ketamine is a Schedule III substance, illegal possession, distribution, or manufacturing carries federal criminal penalties. For a first offense, trafficking Schedule III drugs can result in up to 10 years in prison and fines up to $500,000 for individuals. State penalties vary but can include additional jail time, fines, and a permanent criminal record. Long-term misuse also carries health risks: repeated ketamine abuse has been linked to cognitive and memory impairment, bladder damage, and psychological dependence.